Polymer Adjuvant Self-Assembly for Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein-based vaccines are weakly immunogenic when administered alone and require adjuvants to enhance cellular immune responses, but existing adjuvant delivery methods face challenges in optimizing in vivo activity and stability.
Innovation Solution
Development of an adjuvant comprising Pattern Recognition Receptor agonist (PRRa) molecules linked to polymer chains that can form particles in aqueous conditions or in response to external stimuli, such as temperature changes, allowing for enhanced innate immune activation in lymph nodes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pre-formed particle-based adjuvants are used to enhance innate immune activation, then immune response is improved, but manufacturing complexity and storage stability deteriorate due to particle aggregation and purification difficulties
Solution Approach 1:
The adjuvant system transitions from static pre-formed particles to dynamic unimolecular polymers that self-assemble into particles in situ at the injection site. The polymers remain as single molecules during storage and manufacturing (avoiding aggregation issues) but dynamically form particles when administered, providing both manufacturing simplicity and immune activation efficacy
Solution Approach 2:
The unimolecular polymers are pre-designed with specific molecular weights and structures that enable them to self-assemble into particles of optimal size (1-10 micrometers) upon administration. This preliminary molecular design ensures that particles form at the correct location and time, eliminating the need for complex pre-formulation and purification processes
2Reliability
If pre-formed particle-based adjuvants are used to improve innate immune activation, then immune response is enhanced, but storage stability deteriorates due to particle aggregation over time
Solution Approach 1:
The system dynamically transitions from unimolecular polymer chains during storage to particle structures during administration. This temporal separation ensures stability during storage (as soluble polymers) while maintaining efficacy during use (as particles), resolving the contradiction between storage stability and immune activation
Solution Approach 2:
The physical state of the adjuvant changes from dissolved unimolecular polymers in aqueous solution during storage to self-assembled particle structures upon administration. This parameter change (from molecular to particulate state) occurs in situ, ensuring stability during storage while providing particle-based immune activation when needed
3Speed
If TLR agonists are delivered as small molecules or pre-formed particles, then immune activation is achieved, but local retention and persistent activation deteriorate
Solution Approach 1:
The unimolecular polymers contain multiple TLR agonist molecules nested within their structure (e.g., 10-100 agonists per polymer chain). When these polymers self-assemble into particles in situ, the nested agonists are released in a controlled manner, providing both rapid initial activation and sustained persistent activation as the particles gradually degrade
4Manufacturing precision
If sterile filtration is used to purify vaccine components, then purity is improved, but particle-based adjuvants cannot be used due to size constraints
Solution Approach 1:
The unimolecular polymers are designed to remain as single molecules with sizes suitable for sterile filtration during manufacturing. After filtration, they are administered and only then self-assemble into larger particles in situ, allowing both sterile purification and particle-based adjuvant functionality to coexist
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The adjuvant formulation provides persistent innate immune activation, increased local retention, and enhanced uptake by antigen-presenting cells, leading to improved CD4 and CD8 T-cell responses and immune response durability.
Implementation Method 1
polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli... the polymer is a thermo-responsive polymer
Data Source
AI summary
The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.